These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35710418)

  • 21. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study.
    Gerss J; Roth J; Holzinger D; Ruperto N; Wittkowski H; Frosch M; Wulffraat N; Wedderburn L; Stanevicha V; Mihaylova D; Harjacek M; Len C; Toppino C; Masi M; Minden K; Saurenmann T; Uziel Y; Vesely R; Apaz MT; Kuester RM; Elorduy MJ; Burgos-Vargas R; Ioseliani M; Magni-Manzoni S; Unsal E; Anton J; Balogh Z; Hagelberg S; Mazur-Zielinska H; Tauber T; Martini A; Foell D;
    Ann Rheum Dis; 2012 Dec; 71(12):1991-7. PubMed ID: 22689317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipoprotein cholesterol fractions are related to markers of inflammation in children and adolescents with juvenile idiopathic arthritis: a cross sectional study.
    Bohr AH; Pedersen FK; Nielsen CH; Müller KG
    Pediatr Rheumatol Online J; 2016 Nov; 14(1):61. PubMed ID: 27835952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis.
    Frosch M; Strey A; Vogl T; Wulffraat NM; Kuis W; Sunderkötter C; Harms E; Sorg C; Roth J
    Arthritis Rheum; 2000 Mar; 43(3):628-37. PubMed ID: 10728757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.
    Gohar F; Anink J; Moncrieffe H; Van Suijlekom-Smit LWA; Prince FHM; van Rossum MAJ; Dolman KM; Hoppenreijs EPAH; Ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Foell D; Holzinger D
    J Rheumatol; 2018 Apr; 45(4):547-554. PubMed ID: 29335345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Significance of Myeloid-Related Protein 8/14 as a Predictor for Biological Treatment and Disease Activity in Rheumatoid Arthritis.
    Yunchun L; Yue W; Jun FZ; Qizhu S; Liumei D
    Ann Clin Lab Sci; 2018 Jan; 48(1):63-68. PubMed ID: 29530998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis.
    La C; Lê PQ; Ferster A; Goffin L; Spruyt D; Lauwerys B; Durez P; Boulanger C; Sokolova T; Rasschaert J; Badot V
    RMD Open; 2021 Jun; 7(2):. PubMed ID: 34108235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood calprotectin in children with juvenile idiopathic arthritis: relationship to flare development after discontinuation of treatment.
    Boyko Y; Ivanova V; Vakaruk M; Kozina T; Shevchenko N; Vaizer N; Synoverska O; Chubata O; Marchuk O; Havrylyuk A
    Reumatologia; 2020; 58(4):202-207. PubMed ID: 32921826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trajectories of disease courses in the inception cohort of newly diagnosed patients with JIA (ICON-JIA): the potential of serum biomarkers at baseline.
    Ganeva M; Fuehner S; Kessel C; Klotsche J; Niewerth M; Minden K; Foell D; Hinze CH; Wittkowski H
    Pediatr Rheumatol Online J; 2021 May; 19(1):64. PubMed ID: 33933108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.
    Ter Haar NM; van Dijkhuizen EHP; Swart JF; van Royen-Kerkhof A; El Idrissi A; Leek AP; de Jager W; de Groot MCH; Haitjema S; Holzinger D; Foell D; van Loosdregt J; Wulffraat NM; de Roock S; Vastert SJ
    Arthritis Rheumatol; 2019 Jul; 71(7):1163-1173. PubMed ID: 30848528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum calprotectin (S100A8/9), clinical and ultrasound assessment in patients with juvenile idiopathic arthritis.
    Romano M; Gerloni V; De Lucia O; Piskin D; Giani T; Gattinara M; Borghi MO; Bodio C; Mahler M; Meroni PL; Cimaz R
    Clin Exp Rheumatol; 2021; 39(5):1132-1140. PubMed ID: 34128789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measurement of blood calprotectin (MRP-8/MRP-14) levels in patients with juvenile idiopathic arthritis.
    Bojko J
    Reumatologia; 2017; 55(1):10-14. PubMed ID: 28386137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated levels of serum MRP8/14 in ankylosing spondylitis: associated with peripheral arthritis and active disease.
    Gupta L; Bhattacharya S; Agarwal V; Aggarwal A
    Clin Rheumatol; 2016 Dec; 35(12):3075-3079. PubMed ID: 27738838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum heat shock protein 60 can predict remission of flare-up in juvenile idiopathic arthritis.
    Wu CT; Ou LS; Yeh KW; Lee WI; Huang JL
    Clin Rheumatol; 2011 Jul; 30(7):959-65. PubMed ID: 21340498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study.
    Heiligenhaus A; Klotsche J; Tappeiner C; Sengler C; Niewerth M; Liedmann I; Hoeft S; Walscheid K; Lavric M; Foell D; Minden K
    Rheumatology (Oxford); 2019 Jun; 58(6):975-986. PubMed ID: 30590748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort.
    Glerup M; Rypdal V; Arnstad ED; Ekelund M; Peltoniemi S; Aalto K; Rygg M; Toftedal P; Nielsen S; Fasth A; Berntson L; Nordal E; Herlin T;
    Arthritis Care Res (Hoboken); 2020 Apr; 72(4):507-516. PubMed ID: 30762291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis.
    Alberdi-Saugstrup M; Nielsen S; Mathiessen P; Nielsen CH; Müller K
    Clin Rheumatol; 2017 Jan; 36(1):67-75. PubMed ID: 27562034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.
    Choi IY; Gerlag DM; Herenius MJ; Thurlings RM; Wijbrandts CA; Foell D; Vogl T; Roth J; Tak PP; Holzinger D
    Ann Rheum Dis; 2015 Mar; 74(3):499-505. PubMed ID: 24297376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study of serial serum myeloid-related protein 8/14 as a sensitive biomarker in Takayasu arteritis: a single centre study.
    Goel R; Nair A; Kabeerdoss J; Mohan H; Jeyaseelan V; Joseph G; Danda D
    Rheumatol Int; 2018 Apr; 38(4):623-630. PubMed ID: 29196802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
    Funk RS; Chan MA; Becker ML
    Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.